ReNeuron Group Plc (RENE)-Financial and Strategic SWOT Analysis Review

ReNeuron Group Plc (RENE)-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH81745FSA
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

ReNeuron Group Plc (RENE)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ReNeuron Group Plc (ReNeuron) is a clinical-stage stem cell company which develops innovative stem cell therapies targeting areas of significant unmet medical need. The company's therapeutic candidates in clinical development are focused at treating motor disability as a result of stroke, critical limb ischaemia and the blindness-causing disease retinitis pigmentosa. Its lead CTX stem cell therapeutic candidate is a therapy for treating patients left disabled by a stroke. The company used its exclusive stem cell technologies for developing cell-based therapies for significant disease conditions where the cells can be administered "off-the-shelf" to any fit patient without the requirement for additional immunosuppressive drug treatments. ReNeuron is headquartered in Surrey, the UK.

ReNeuron Group Plc Key Recent Developments

Jul 19,2017: ReNeuron Group: Board change

Jun 29,2017: ReNeuron Group: Preliminary Results for the Year Ended 31 March 2017

May 11,2017: ReNeuron awarded major UK cell therapy manufacturing grant

Apr 21,2017: ReNeuron successfully develops cryopreserved formulation of its retinal stem cell therapy candidate and expands ophthalmology programmes

Jan 23,2017: Merck Announces Emerging Biotech Grant Program Winners

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

ReNeuron Group Plc-Key Facts 6

ReNeuron Group Plc-Key Employees 7

ReNeuron Group Plc-Key Employee Biographies 8

ReNeuron Group Plc-Major Products and Services 9

ReNeuron Group Plc-History 10

ReNeuron Group Plc-Company Statement 11

ReNeuron Group Plc-Locations And Subsidiaries 14

Head Office 14

Other Locations & Subsidiaries 14

Section 2-Company Analysis 15

ReNeuron Group Plc-Business Description 15

ReNeuron Group Plc-Corporate Strategy 16

ReNeuron Group Plc-SWOT Analysis 17

SWOT Analysis-Overview 17

ReNeuron Group Plc-Strengths 17

ReNeuron Group Plc-Weaknesses 18

ReNeuron Group Plc-Opportunities 19

ReNeuron Group Plc-Threats 20

ReNeuron Group Plc-Key Competitors 21

Section 3-Company Financial Ratios 22

Financial Ratios-Capital Market Ratios 22

Financial Ratios-Annual Ratios 23

Performance Chart 25

Financial Performance 25

Financial Ratios-Interim Ratios 26

Financial Ratios-Ratio Charts 27

Section 4-Company's Lifesciences Financial Deals and Alliances 28

ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 28

ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 29

ReNeuron Group Plc, Recent Deals Summary 30

Section 5-Company's Recent Developments 31

Jul 19, 2017: ReNeuron Group: Board change 31

Jun 29, 2017: ReNeuron Group: Preliminary Results for the Year Ended 31 March 2017 32

May 11, 2017: ReNeuron awarded major UK cell therapy manufacturing grant 33

Apr 21, 2017: ReNeuron successfully develops cryopreserved formulation of its retinal stem cell therapy candidate and expands ophthalmology programmes 34

Jan 23, 2017: Merck Announces Emerging Biotech Grant Program Winners 35

Dec 05, 2016: ReNeuron: Interim Results for the six months ended 30 September 2016 36

Sep 06, 2016: ReNeuron: AGM Trading Update 39

Jul 07, 2016: ReNeuron Group Reports Preliminary Results for the Year Ended 31 March 2016 40

Feb 23, 2016: ReNeuron relocates to South Wales 41

Feb 01, 2016: ReNeuron receives notice of grant of key US patent on its cell cryopreservation technology 42

Section 6-Appendix 43

Methodology 43

Ratio Definitions 43

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

ReNeuron Group Plc, Performance Chart (2013-2017) 25

ReNeuron Group Plc, Ratio Charts 27

ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 28

ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 29

List of Tables

ReNeuron Group Plc, Key Facts 6

ReNeuron Group Plc, Key Employees 7

ReNeuron Group Plc, Key Employee Biographies 8

ReNeuron Group Plc, Major Products and Services 9

ReNeuron Group Plc, History 10

ReNeuron Group Plc, Subsidiaries 14

ReNeuron Group Plc, Key Competitors 21

ReNeuron Group Plc, Ratios based on current share price 22

ReNeuron Group Plc, Annual Ratios 23

ReNeuron Group Plc, Annual Ratios (Cont...1) 24

ReNeuron Group Plc, Interim Ratios 26

ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 28

ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 29

ReNeuron Group Plc, Recent Deals Summary 30

Currency Codes 43

Capital Market Ratios 43

Equity Ratios 44

Profitability Ratios 44

Cost Ratios 45

Liquidity Ratios 45

Leverage Ratios 46

Efficiency Ratios 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ReNeuron Group Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license

Single User License
USD 125 INR 8073
Site License
USD 250 INR 16145
Corporate User License
USD 375 INR 24218

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com